EFFICACY OF TICLOPIDINE ON PLATELET AGGREGABILITY IN PATIENTS WITH A VVI PACEMAKER
Feridun KOŞAR, MD* Abdurrahman OĞUZHAN, MD**
.
Abstract
Several studies have previously reported an increased platelet aggregability in patiens with VVI pacemakers; moreover, some authors have showed that antiplatelet drugs may be effective in reducing platelet aggregation, thus suggesting an increased formation of platelet activation markers in these patients. In this respect, platelet aggregability was investigated in twenty five VVI patients and fifteen control subjects. In addition, p-thromboglobulin (p-TG) and platelet factor 4 (PF4) plasma levels were measured to determine the degree of platelet activation before and after ticlopidine treatment.
Plasma p-TG and PF4 levels were significantly increased in VVI patients as compared with control subjects ( 147.84 ± 44.15 vs 75.64 ± 31.77, P < 0.001 and 62.90 ± 71.93 vs 21.88 ± 11.10, p < 0,001; respectively). Additionally, plasma p- TG and PF4 levels after ticlopidine treatment were significantly decreased as compared with that before ticlopidine treatment (43.69 ± 16.56 vs 147.84 ± 44.45, P < 0.001 and 15.07 ±7.17 vs 62.90 ± 71.93, P < 0.001; respectively).
Our data confirm an increased of platelet aggregability in patients with VVI pacemakers and show the efficacy of ticlopidine in reducing platelet aggregability.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
